Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a Chinese biopharmaceutical company headquartered in Chengdu, Sichuan Province. The firm operates as a subsidiary of Sichuan Kelun Pharmaceutical Group, a major Chinese pharmaceutical manufacturer founded in 1996. The parent group is publicly traded on the Shenzhen Stock Exchange under ticker 002422. The company's pipeline spans generics, innovative drugs, and biologics, with a strong focus on oncology, including monoclonal antibodies and antibody-drug conjugates. Public records indicate the firm has filed for over 40 new drug applications in China, with several programs in clinical trials. The company also manufactures active pharmaceutical ingredients and finished dosage forms for domestic and international markets. As a subsidiary, Kelun-Biotech does not disclose AUM or assets; financial data is consolidated into the parent group's filings. The ADR traded over-the-counter in the US under ticker KNKBF until 2023, when the company delisted amid regulatory changes. No major operational announcements have been reported in the past 24 months by major financial media. The structural differentiator for Kelun-Biotech is its position as a vertically integrated Chinese pharma player, combining generic manufacturing scale with an innovative pipeline. Its ADR program historically gave foreign investors a public-equity window into a company otherwise accessible only via China's A-share market.